Chimeric Antigen Receptor (CAR) T cell therapy is an innovative treatment that encompasses the reengineering of white blood cells (WBC) of a cancer patient’s to fight the malignant cells by identifying them. CAR-T cell therapy is approved for certain types of blood cancer. The blood cancer type, multiple myeloma affects plasma cells. In multiple myeloma, the malignant cells accrue in the bone marrow (the spongy, soft tissue at the middle of bones), gathering out the normal plasma cells that help fight contamination. These malicious plasma cells then produce M protein, an atypical antibody that offers no advantage to the body and might cause kidney damage, tumors, bone obliteration, and reduced immune function. The high level of M protein in blood denotes the characteristics of multiple myeloma.
The Multiple Myeloma is infrequently curable, but it is an extremely manageable disease that has seen speedy medical development over the past few years. The development of the Multiple Myeloma Research Foundation (MMRF) has improved the research activities to develop the most promising treatments for multiple myeloma. CAR T-cell therapy for multiple myeloma is one advanced immunotherapy to program the immune system to attack cancer. The CAR-T Cell therapy for multiple myeloma market size is expected to reach US$ xx million by 2030, growing at a CAGR of xx% over the forecast period. The rising prevalence of multiple myeloma is anticipated to foster the growth CAR T-cell therapy for multiple myeloma market globally. The presence of potential pipeline drugs to treat multiple myeloma is expected to boost the growth of the market in the coming years. However, high costs associated with CAR T-cell therapy owing to the high cost of research and development activities may hamper the growth of the market substantially over the estimated time frame.
The Global CAR-T cell therapy for multiple myeloma market is segmented based on therapy type, and country. Based on the therapy type, the CAR T-cell therapy for multiple myeloma market is segmented into JNJ-68284528 (LCAR-B38M), Bb2121, CAR-CD44V6, P-BCMA-101, and others. Currently, there is no approved CAR- T cell therapy for multiple myeloma in the market. The presence of strong candidates under development stages is expected to accelerate the growth of the market in the coming years. Additionally, various research firms are trying combination therapy to treat multiple myeloma. The recent development in the understanding of immunology has permitted companies to develop new immunotherapeutic methods, that are effective in various cancers, including multiple myeloma. Based on the country, the market is studied across The US, Germany, France, the UK, Italy, and the Rest of the World.
The key players of this market include Bluebird bio/Celgene, Poseida Therapeutics, MolMed S.p.A., Janssen Research & Development, Celgene Corporation, CARsgen Therapeutics, Cartesian Therapeutics, and Precision BioSciences. The growing research and development activities and rising focus of biopharmaceutical companies to develop advanced therapy such as CAR-T cell therapy for multiple myeloma are expected to foster the market growth in the coming years. Additionally, the market approval of pipeline candidates in the coming years is expected to propel the growth of CAR-T cell therapy for multiple myeloma market globally.
Global CAR-T Cell Therapy for Multiple Myeloma Market by Therapy Type
- JNJ-68284528 (LCAR-B38M)
Global CAR-T Cell Therapy for Multiple Myeloma Market Based on Country
- The US
- The UK
- Rest of World
Major Qualitative Insights
- Industry Overview
- Future Trends in CAR-T Cell Therapy for Multiple Myeloma Market
- CAR-T Cell Therapy for Multiple Myeloma Market Drivers and Challenges
- CAR-T Cell Therapy for Multiple Myeloma Market Size and Forecast
- Clinical Trial/Pipeline Analysis
- CAR-T Cell Therapy for Multiple Myeloma Key News/Industry Activities
- Major Mergers & Acquisition in CAR-T Cell Therapy for Multiple Myeloma Industry
- Competitive Landscape
- Company Overview
- Latest Strategic Developments
InsightAce Analytic follows a comprehensive and standard market research methodology focused on offering the most accurate and precise market insights. The company focuses on data triangulation using statistical models that helps company to generate market estimation with minimum deviation. The methodology followed for all our market studies include:
- Primary Research (Industry experts and KOLs interviews)
- Secondary Research (Collection of qualitative and quantitative data from desk research)
- Statistics Data Analysis Models
Give us a call
North America: +1 551 226 6109
Asia: +91 79 72967118